Navigation Links
Blackrock Microsystems Obtains Expanded 510(k) to Market NeuroPort System

Blackrock's NeuroPort Biopotential Neural Signal Processing System enables acute monitoring, signal detection and analysis to facilitate development of new clinical therapies with the potential to improve diagnosis and treatment of a wide range of brain disorders including Epilepsy and Parkinson's disease. The NeuroPort System is uniquely capable of monitoring from as many as 256 channels, with the potential to be scalable to more than a thousand channels (in increments of 256 channels), to improve intracranial high-channel direct recording of brain activity.The enhanced NeuroPort System offers physicians and neuroscience researchers richer data related to spatial and temporal resolution at the level of single neurons.

Salt Lake City, Utah (PRWEB) July 15, 2009 -- Blackrock Microsystems LLC today announced that it has received a new, expanded 510(k) marketing approval from the U.S. Food and Drug Administration. The new labeling allows the NeuroPort Biopotential Neural Signal Processor (NeuroPort System) to be used with electrodes supplied by users, as well as with the implantable NeuroPort Cortical Microelectrode Array (NeuroPort Array) covered by a previous 510(k). In addition, the new 510(k) for the NeuroPort System has been expanded to include its use in medical applications beyond brain monitoring.

The biopotential signals that the NeuroPort System is designed to detect, record and analyze include electrocorticography (ECoG), electroencephalography (EEG), electromyography (EMG), electrocardiography (ECG), electrooculography (EOG) and Evoked Potential (EP).
The NeuroPort System provides neuroscientists, neurologists and neurosurgeons an innovative and unequalled resource to detect, transmit and analyze brain activity in a wide range of intra-operative, outpatient and research settings. Significant advantages of the NeuroPort System include, among others:

  • Real-time access to data;
  • Scalable, 256-channel channel recording capability;
  • Automatic spike sorting with multiple sorting options;
  • Open data file format that is compatible with third-party applications; and
  • Synchronous filtering to remove non-biological signals.
"Our 510(k) marketing approval significantly expands the potential medical applications of our NeuroPort Signal Processing platform, which supports our continued drive to develop products to support closed-loop control for therapeutic and prosthetic applications," said Chief Executive Officer Andrew Gotshalk. "The NeuroPort System enables us to work directly with leading clinicians to develop applications of our technology to monitor, diagnose and treat a wide range of debilitating diseases and conditions that, today, are poorly managed and diagnosed."

In March 2009, Blackrock Microsystems acquired worldwide rights to the NeuroPort acute monitoring platform technology from Cyberkinetics Neurotechnology Systems, Inc., formerly of Foxborough, Massachusetts. The NeuroPort System platform is currently used in the BrainGate Neural Interface System (approved under IDE), which is designed for chronic use in people with spinal cord injuries, stroke and neurodegenerative conditions. Cyberkinetics previously obtained 510k clearance to market the NeuroPort System in April 2005, though its use at the time was limited exclusively to acute (< 30 days) intracranial monitoring with a 96-channel microelectrode array (the Utah array).

About Blackrock Microsystems LLC
Blackrock Microsystems, a privately held company, is a leading global marketer in intelligent microsystems that aid neuroscience researchers and physicians in the development of improved medical solutions for the diagnosis and treatment of serious central nervous system diseases and conditions. Blackrock also markets a broad range of neural monitoring equipment to neuroscience researchers worldwide. Additional information is available from the Company's website at


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
2. NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases
3. NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds
4. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
5. China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief
6. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
7. Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical
8. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
9. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
10. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
11. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
Post Your Comments:
Related Image:
Blackrock Microsystems Obtains Expanded 510(k) to Market NeuroPort System
(Date:11/30/2015)... - BioAmber Inc. (NYSE: BIOA ), a leader in renewable ... Act on Climate Pledge, alongside more than 140 companies from ... Administration to demonstrate an ongoing commitment to climate action and ... Paris climate negotiations. ... . --> BioAmber uses biotechnology to convert ...
(Date:11/30/2015)... Mass. , Nov. 30, 2015 ... HART ), a biotechnology company developing bioengineered organ ... received written notification from The NASDAQ Stock Market ... bid price requirements. The letter noted that as ... HART,s common stock having exceeded $1.00 per share ...
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine ... Jurassic World: The Exhibition, opening in March 2016 at Melbourne Museum in Melbourne, ... tour including several North American tour dates. The Exhibition is based on Universal ...
(Date:11/30/2015)... 30, 2015 TapImmune, Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for ... it will be presenting at the 8 th ... at 2.30 PM PT. Dr. John N. Bonfiglio ... be giving the presentation and will join TapImmune management ...
Breaking Biology Technology:
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
Breaking Biology News(10 mins):